Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Finland study of tocilizumab in active rheumatoid arthritis with inadequate response to non-biologic DMARDs
2008-004126-16Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jul 2008; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-004126-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004126-16.